Company Deep Dive

Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.

View Deep Dive

NVO

Strong Buy

Novo Nordisk A/S · Healthcare · Denmark · $201.6B · Avg Vol: $579M/d

88
StockRank
Get insider-trade alerts
Q
75
V
55
M
56
P/E (TTM)
11.5x
ROE
59.8%
D/E
0.6x
Dividend %
3.9%
Dir. Trades · 180d
None →
Buybacks · 180d
None →

COMPANY DESCRIPTION

Novo Nordisk A/S is a global healthcare company with a leading position in diabetes care, obesity, and other serious chronic diseases, renowned for its innovative pharmaceutical products like Ozempic and Wegovy. Its competitive moat is built on extensive R&D, strong patent protection, a global distribution network, and decades of specialization in metabolic disorders. Novo Nordisk is a market leader in diabetes and obesity pharmaceuticals, driven by continuous innovation and expanding therapeutic areas.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue27.4B36.0B45.0B47.9B20.4%51.4B46.3B47.1B-0.9%
EPS1.902.893.513.5723.4%4.103.583.41-2.3%
Shares4.5B4.5B4.4B4.4B-1.3%3.3B———
Debt4.0B4.2B15.9B20.3B71.9%21.9B———
Equity12.9B16.5B22.2B30.1B32.5%————
Op CF12.2B16.9B18.8B18.5B14.7%20.6B———
Inv CF-3.9B-6.8B-20.0B-12.3B—————
Fin CF-8.0B-9.8B1.4B-4.4B—————
Loading 1Y...
PRICE (1Y)-8.1%
44.2846.1147.9449.7851.61Jul 20Aug 10Aug 28
SMA 50SMA 200

Close
$45.61
RSI (14)
42.7
52W High
$61.11
From 52W High
0.7%

SCORE BREAKDOWN

Quality
75
ROIC
45.7%98.8
ROE
59.8%97.9
GP/Assets
51.0%87.5
Op. Margin
42.5%96.9
FCF/Assets
8.8%83.0
Piotroski
550.3
Int. Cover
32.0x75.5
D/E Ratio
0.63x25.2
Current Ratio
0.87x8.0
Value
55
P/E (TTM)
11.5x84.9
EV/EBITDA
11.2x62.5
P/FCF
27.7x46.2
P/B
38.7x2.9
P/S
4.1x48.6
Div Yield
3.9%82.1
Momentum
56
52W High %
75%56.4
RS 6M
15%77.2
SMA 50/200
1.05x70.7
EPS Rev 4W
+2.0%68.4
EPS Rev 12W
+2.2%73.6
EPS Improve
-16%16.2
Q Growth
-21%22.7

FUNDAMENTALS

Market Cap
$201.6B
P/E (Forward)
13.7x
Gross Margin
82.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NVO are excluded.

TickerCompanyMkt CapStockRankSignal
NVONovo Nordisk A/S(you)$201.6B88Strong Buy
AMGNAmgen Inc.$233.8B89Strong Buy
PFE.MXPfizer Inc.$160.3B88Strong Buy
GILD.MXGilead Sciences, Inc.$181.0B85Strong Buy
NOVN.SWNovartis AG$299.9B86Strong Buy
ROP.SWRoche Holding AG$367.3B88Strong Buy
MRK.MXMerck & Co., Inc.$372.4B91Strong Buy
GSK.LGSK plc$100.5B87Strong Buy
AZNAstraZeneca PLC$252.3B77Buy
ABBVAbbVie Inc.$451.5B87Strong Buy

Peer medians: ROE 1.9% · P/E 24.0x · Gross margin 52.1%

Novo Nordisk A/S (NVO): Stock Score Summary

Novo Nordisk A/S (NVO) has a MoatMap StockRank of 88/100 based on Quality (75/100), Value (55/100), and Momentum (56/100) factor scores. The current signal is STRONG BUY.

Novo Nordisk A/S is a global healthcare company with a leading position in diabetes care, obesity, and other serious chronic diseases, renowned for its innovative pharmaceutical products like Ozempic and Wegovy. Its competitive moat is built on extensive R&D, strong patent protection, a global distribution network, and decades of specialization in metabolic disorders. Novo Nordisk is a market leader in diabetes and obesity pharmaceuticals, driven by continuous innovation and expanding therapeutic areas.

Key Financial Metrics

Price$45.61
Market Cap$201.6B
P/E (TTM)11.51
P/E (Forward)13.75
Price/Book38.74
Return on Equity59.8%
Return on Invested Capital45.7%
Debt/Equity0.63x
Gross Margin82.0%
Operating Margin42.5%
Revenue Growth2.1%
Dividend Yield3.9%
Free Cash Flow$7.3B

Novo Nordisk A/S operates in the Drug Manufacturers - General industry, part of the Healthcare sector (Denmark).

Frequently Asked Questions

What is Novo Nordisk A/S’s (NVO) StockRank?
MoatMap’s StockRank for Novo Nordisk A/S (NVO) is 88/100, with a Strong Buy signal. It is a composite of Quality (75), Value (55), and Momentum (56) factor ranks across MoatMap’s 20,000+ stock universe.
Does Novo Nordisk A/S have an economic moat?
Novo Nordisk A/S (NVO) has a Quality factor score of 75/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Novo Nordisk A/S a buy, hold, or sell?
MoatMap’s current signal for Novo Nordisk A/S (NVO) is Strong Buy, based on a StockRank of 88/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Novo Nordisk A/S in?
Novo Nordisk A/S (NVO) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry (Denmark).
Browse all ranked stocksNVO deep dive reportAI ChampionsHow we score stocksSense-check another stock